Journal article
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
Abstract
BACKGROUND: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coronary syndrome in 18 924 patients. Alirocumab reduced first occurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic …
Authors
Szarek M; Steg PG; DiCenso D; Bhatt DL; Bittner VA; Budaj A; Diaz R; Goodman SG; Gotcheva N; Jukema JW
Journal
Circulation Cardiovascular Quality and Outcomes, Vol. 12, No. 11,
Publisher
Wolters Kluwer
Publication Date
November 2019
DOI
10.1161/circoutcomes.119.005858
ISSN
1941-7713
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Acute Coronary SyndromeAngina, UnstableAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsBiomarkersCholesterol, HDLCholesterol, LDLDrug Therapy, CombinationDyslipidemiasHospital MortalityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionPatient AdmissionPatient ReadmissionRisk AssessmentRisk FactorsTime FactorsTreatment Outcome